Fluoroquinolone (FQ) and cephalosporin (CEP) resistance among Enterobacteriaceae has been increasingly reported. FQ resistance occurs primarily through mutations in DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE). CEP resistance in Enterobacteriaceae is mainly due to the production of CTX-M type extended-spectrum b-lactamases. Although prevalence and mechanisms of FQ and CEP resistance in Enterobacteriaceae such as Escherichia coli have been well studied, little is known about Proteus mirabilis in Japan. In this study, we assessed the prevalence and mechanism of FQ resistance in Japanese clinical isolates of P. mirabilis. We collected 5845 P. mirabilis isolates from eight hospitals between 2000 and 2013. Prevalence of FQ resistance was calculated as the annual average percentage of all P. mirabilis isolates. We and ParE (D420N). Our findings suggest that substitutions in GyrA (E87) and ParE (D420) have played an important role in the emergence of high-level LVXresistant P. mirabilis isolates (MIC, 32 mg/L) in Japan.
Introduction
Proteus mirabilis is one of the most common causative agents of urinary tract infections (UTIs). It can lead to pneumonia in debilitated or immunocompromised patients, and represents an important cause of nosocomial infections [1] .
Fluoroquinolones (FQs), cephalosporins (CEPs), and co-trimoxazole are used as first-line agents against cystitis [2] . FQs are the most commonly used antibiotics for the treatment of a wide range of infections including UTIs in western Europe, North America, and Japan [3, 4] . As a result of their widespread use, rates of FQand CEP-resistant Enterobacteriaceae have increased worldwide [5, 6, 7, 8] . Data from the European Antimicrobial Resistance Surveillance Network confirmed a significant increase in FQ resistance across Europe since 2001 [9] . Furthermore, the prevalence of CEP-resistant Escherichia coli has also increased worldwide due to the production of extended-spectrum b-lactamases (ESBLs), particularly CTX-M enzymes [6, 10] . Although P. mirabilis wild-type strains are usually susceptible to FQs, increased resistance has been observed in clinical isolates [2, 11, 12, 13, 14] . In addition, we previously reported a regional outbreak of CTX-M-2 enzyme-producing P. mirabilis in Japan [15] .
The mechanisms of resistance to FQs identified so far in clinical isolates include mainly alterations of target proteins, such as DNA gyrase (encoded by gyrA and gyrB) and topoisomerase IV (encoded by parC and parE), and decreased drug accumulation due to efflux pumps or changes in outer membrane [16, 17] . The primary target of FQs in several species of Enterobacteriaceae such as E. coli is GyrA. Specific point mutations in gyrA are associated with resistance to FQs [16, 18] . Additional mutations in DNA gyrase or topoisomerase IV contribute to high-level forms of resistance [19, 20] . Genetic characterisation of these mutations has been defined by DNA sequence analysis of clinical isolates; accordingly, highly conserved regions are designated as quinolone resistance-determining regions (QRDRs) [16, 21] . QRDRs associated with resistance to FQs in P. mirabilis include mostly known substitutions in GyrA (S83) and ParC (S80) [22, 23] . Additional mutations in GyrB (S464) confer high-level FQ resistance [22, 23] . However, the exact role of QRDRs, especially those on ParE, in FQ-resistant P. mirabilis is unclear and more data from clinical isolates are required to identify the mechanism of resistance.
Although the prevalence and mechanisms of FQ resistance are well established in E.
coli, little is known about P. mirabilis. Hence, in this study, we carried out a survey to assess the prevalence and mechanisms of resistance to FQs among P. mirabilis clinical isolates in Japan between 2000 and 2013. Amino acid sequences of the QRDRs on GyrA, GyrB, ParC, and ParE from clinical isolates were compared to the type strain and susceptible isolates. In addition, amino acid substitution profiles were studied to determine associations between QRDR mutations, FQ resistance, and levofloxacin (LVX) minimum inhibitory concentrations (MICs).
Materials and methods
2.1. Epidemiological study of drug-resistant P. mirabilis P. mirabilis isolates were collected from eight hospitals located in different Japanese cities between 2000 and 2013. The bed capacity of these hospitals exceeded 300 units. All strains were isolated from either infections or colonization/screening and only one isolate per patient was included in the study. The isolates were identified and initial susceptibilities of FQs and CEPs were determined using the MicroScan WalkAway System (Beckman Coulter, Inc.). The annual prevalence of resistance to FQs or CEPs was calculated as the annual average percentage of all P. mirabilis isolates resistant to LVX or cefotaxime (CTX). Resistance to LVX or CTX was defined by a MIC 8 mg/L or 4 mg/L, respectively [24] .
Bacterial strains and determination of antimicrobial susceptibility
A total of 100 non-duplicate isolates were selected from the eight hospitals within different periods during 2004e2005. Antimicrobial susceptibility to the following drugs was determined by the agar dilution method according to the Clinical Laboratory Standards Institute guidelines using E. coli ATCC 25922 as a quality control strain [24] : nalidixic acid (NAL), LVX, ciprofloxacin (CIP), norfloxacin (NOR), ofloxacin (OFX), sparfloxacin (SPX), and sitafloxacin (STX). To evaluate the contribution of efflux pumps to FQ resistance, MICs were measured in the presence of the efflux pump inhibitor carbonyl cyanide m-chlorophenylhydrazone (CCCP). CCCP was incorporated in MuellereHinton agar at a concentration of 12.5 mM. Fifty isolates, whose FQ susceptibility was not affected by CCCP, were selected among 100 isolates and were further characterised in terms of genotype and MICs for LVX.
PCR amplification and sequencing of gyrA, gyrB, parC, and parE QRDRs
Twenty-three isolates showing susceptibility or intermediate resistance to LVX (MIC, 4 mg/L), and 27 LVX-resistant (MIC, 8 mg/L) P. mirabilis isolates were analysed for QRDR mutations in gyrA, gyrB, parC, and parE using PCR amplification and direct DNA sequencing. Oligonucleotide primers for PCR amplification of P. mirabilis ATCC29906 type strain genes were designed based on the alignment of the following known DNA sequences (accession numbers) in the GenBank database: AF397169 (gyrA), AF503506 (gyrB), AF363611 (parC), and AF503505 (parE). The primers were as follows: gyrA, forward, 5
0 -ACTGAAGC-
Cycling conditions were as follows: denaturation at 94 C for 10 min, followed by 35 amplification cycles (94 C for 30 s, 54 C for 30 s, 72 C for 30 s), and a final elongation step at 72 C for 5 min. DNA sequences were analysed and compared to P. mirabilis ATCC29906 using the NCBI BLAST tool. The presence of plasmid-mediated quinolone resistance qnr genes (qnrA, qnrB, qnrC, qnrD, and qnrS), qepA, and aac(6 0 )-Ib-cr was determined by PCR amplification [25, 26] .
Results and discussion

Prevalence of resistance to LVX, CTX, or both in P. mirabilis isolates collected between 2000 and 2013
We conducted a 14-year survey of FQ resistance by screening 5845 clinical isolates of P. mirabilis. The frequency of P. mirabilis LVX-and/or CTX-resistant isolates for each year is shown in Fig. 1 [14] . We previously reported that almost all CEP-resistant P. mirabilis in Japan harboured a plasmid-borne bla CTX-M-2 gene [15] . The prevalence of P. mirabilis resistant to both LVX and CTX also increased. Our data indicate that 87.9 % of FQ-resistant isolates from the present 14-year survey were also resistant to CEP. These drug-resistant P. mirabilis are highly prevalent in Japan, where their frequency has remained almost unchanged since 2004.
This trend towards increased resistance to LVX is similar to that reported previously for hospital isolates of E. coli [28] . FQ resistance has been closely associated with ESBL production, which may derive from the prior heavy use of antibiotics [29, 30] . Both FQ-and CEP-resistant pathogens gain a survival advantage during antibiotic treatment with FQ or CEP. The resulting selective pressure favours these pathogens' survival and spreading [6] . The worldwide dissemination of FQ-and CEPresistant pathogens is a significant challenge to antibiotic treatment and infection control policies. E. coli is, like P. mirabilis, a common cause of UTIs and is also treated with FQs and CEPs. The widespread cumulative use of FQs may be accelerating the development of resistance to these agents, and may represent the driving force behind the stepwise increase in resistance among Enterobacteriaceae [31] .
Whereas the percentage of E. coli isolates resistant to LVX has been higher than that of CEP-resistant strains [10] , in the present study we observed the opposite trend for P. mirabilis. mirabilis isolates from Japan: -, total number of P. mirabilis isolates per year; B, % of CTX-and LVX-resistant P. mirabilis isolates per year; ,, % of CTX-resistant P. mirabilis isolates per year;
O, % of LVX-resistant P. mirabilis isolates per year. Isolates resistant to LVX presented a slightly higher rate than those resistant to both LVX and CTX. Most LVX-resistant isolates were also resistant to CTX. The histogram is linked to the 2 nd Y-axis representing the number of P. mirabilis isolates. and TK1086 were super-resistant to SPX (MIC, > 512 mg/L). The MP10 strain had a substitution in ParC (E84K) in addition to substitutions from low-level resistant strains (such as GyrA S80I, GyrB E466D, ParC S80I, and ParE V364I). The TK1086 strain presented a substitution in GyrB (E466K) in addition to substitutions from low-level resistant strains (such as GyrA S83I, GyrB S464I, ParC S80I and E84D, and ParE V364I). These two strains' extremely high resistance to SPX may depend on substrate specificity derived from the additional substitutions in GyrB (E466) and ParC (E84). The highest-level LVX-resistant strains showed [33] . Previous studies suggested that substitutions in GyrB (S464) and ParC (S80) might affect high-level FQ resistance. However, in P. mirabilis, the corresponding E. coli substitutions in GyrA (S83) and ParC (S80) did not significantly correlate with high-level resistance to FQs [22, 23] . In this study, substitutions in P. mirabilis GyrA (E87) and ParE (D420) had a significant effect on high-level resistance to FQs (MIC, 32 mg/L). P. mirabilis
Amino acid substitutions in
GyrA, GyrB, ParC, and ParE QRDRs have been compared to analogous sequences in E. coli [30] , but showed low homology, particularly due to the high variability of ParE compared to ParC [30] . Such low homology could affect the correlation between QRDR mutations and FQ MICs, as this association forms the basis of the FQ-resistant mechanism in Enterobacteriaceae.
Conclusions
In conclusion, we conducted a survey of the prevalence of LVX-resistant P. mirabilis and investigated the mechanism of FQ resistance. In Japan, the prevalence of FQresistant P. mirabilis has gradually increased and has remained high (13.3e17.5%) since 2004. To tackle this problem, we must carefully monitor drug-resistant P. mirabilis, and limit and reduce the use of antibiotics. Our findings suggest that mutations in GyrA (E87) and ParE (D420) play an important role in the emergence of high-level FQ resistance in clinical isolates of P. mirabilis. This is the first report describing an association between the QRDRs of ParE and FQ resistance in P.
mirabilis.
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